Tag Archives: Immunity

Natural Immunity Superior to Vaccination Against Infection in Children: Study

Children with natural immunity were better protected from COVID-19 infection and hospitalization than children who were vaccinated, according to a new study.

Children aged 5 to 11 with post-infection protection, or natural immunity from an infection with Omicron or a subvariant, and no vaccination had 88.4 percent protection against reinfection, researchers in North Carolina found. That was compared to 59.7 percent protection against Omicron from a primary series of a messenger RNA vaccine, or two doses of vaccine from Pfizer or Moderna, among the uninfected.

The protection remained higher over time until month eight when the protection from natural immunity among the unvaccinated was estimated to be 18.8 percent and the protection from vaccination was pegged at 22.5 percent.

Fifty percent effectiveness is considered the threshold for an effective vaccine, according to the U.S. Food and Drug Administration and the World Health Organization, but the effectiveness of the shots remained above that bar for just one month, the researchers found.

A monovalent booster, or a discontinued booster, elevated the protection for the vaccinated, including children with a previous infection, by just 24.4 percent after one month, dipping to 19.3 percent after five months. A bivalent booster, or one of the new shots cleared in the fall of 2022, boosted the protection by 76.7 percent after one month but the shielding fell to 47.3 percent on top of the original series after one more month.

Researchers did not provide separate estimates for the naturally immune and unvaccinated, and the vaccinated and infected, against hospitalization and death.

They pegged natural immunity for the 5 to 11 group against hospitalization and death at 87.5 percent after one month, compared with 73.3 percent from a primary series. After three months, natural immunity was estimated at 83.8 percent protection versus 39.3 percent from vaccination; after six months, natural immunity was pegged at 76.2 percent, compared to 2.9 percent for vaccination.

Even though the vaccines are authorized for the prevention of COVID-19, they have become increasingly worse at preventing infection. Authorities have shifted to promoting them as a tool to prevent severe disease, but that protection has also become subpar against Omicron and its subvariants, real-world data and studies show.

The waning effectiveness prompted not only the authorization of boosters with the same formulation as the primary series, but, later, the authorization without clinical data of new boosters aimed at the BA.4 and BA.5 subvariants of Omicron for all Americans aged 6 months and older.

The North Carolina researchers drew from The North Carolina COVID-19 Surveillance System, which contains testing data and COVID-related hospitalization and death information, as well as the COVID-19 Vaccine Management System, which holds vaccination records. The study focused on North Carolina residents 11 years of age and younger, from Oct. 29, 2021, to Jan. 6, 2023. They estimated the effectiveness of vaccination and natural immunity against infection, hospitalization, and death.

Researchers did not provide estimates of booster effectiveness against hospitalization and death. They said there was only one hospitalization and no deaths after receipt of a booster dose.

The study population was primarily unvaccinated because most children in the United States have not received a vaccine.

0–4 Year-Olds

Data from children aged up to 4 years was also analyzed.

The protection from Omicron infection against reinfection among all children was estimated at 83.1 percent after one month. It was pegged at 55.7 percent one month after two doses of a vaccine among the uninfected. At five months, the former was 69.6 percent and the latter was 58.6 percent.

Natural immunity in the youngest age group after an Omicron infection was estimated at 63.3 percent against hospitalization and death one month later, remaining above 50 percent after 10 months.

Researchers included both the vaccinated and unvaccinated in the naturally immune group and did not provide a separate estimate of the protection the unvaccinated and naturally immune enjoyed.

Researchers did not provide an estimate of effectiveness for a primary series or boosters among the population against hospitalization and death.

The study was published as a preprint on Jan. 19.

Researchers said the study showed that “previous SARS-CoV-2 infection induced strong immunity against future infection, although the immunity waned gradually over time” and that “omicron infection induced strong immunity in both vaccinated and unvaccinated children.” SARS-CoV-2 causes COVID-19.

The researchers also said the results showed vaccination “was effective against omicron infection, hospitalization, and death, although the effectiveness waned over time” and that boosters “were effective.”

“Our study showed that the additional benefits of vaccination were similar between previously infected and previous uninfected children,” Dan-yu Lin, a professor in the University of North Carolina’s Department of Biostatistics, told The Epoch Times via email.

“Serious side effects are very rare. The benefits of vaccination outweighs the risk of side effects,” he added. The study did not evaluate vaccine safety or COVID-19 symptoms and Lin declined to provide evidence for the risk-benefit statement.

Limitations of the research include researchers wrongly believing that the Pfizer primary series for children aged 0 to 4 is only two doses. It’s actually three doses (pdf), because a two-dose regimen didn’t induce an adequate immune response, according to Pfizer. The third dose is a bivalent as of late 2022.

Zachary Stieber is a senior reporter for The Epoch Times based in Maryland. He covers U.S. and world news.

Read original article here

A U of T epidemiologist on the myth of immunity debt and the real reason everyone’s getting sick

“I was appalled to see the prime minister making those comments”: A U of T epidemiologist on the myth of immunity debt and the real reason everyone’s getting sick

Colin Furness debunks the popular theory and explains how Covid-19 may be weakening our immune systems in the long run

If you have a kid at home, there’s a good chance they spent the last couple of months snotty, feverish, barfy or worse. Young people in particular have been pummelled by the tridemic of RSV, influenza and Covid-19—and you’ve probably heard that “immunity debt” is to blame. Even Justin Trudeau has parroted this popular theory that our immune systems have gotten weak after two years of coddling behind masks and under lockdowns. There’s just one problem: “It is totally, totally wrong,” says Colin Furness, an epidemiologist at the University of Toronto’s Faculty of Information who believes that Covid infections, not public health measures, are to blame for weakened immunity. Here, he explains why.


For weeks now, it has felt like the entire city is sniffling or worse. Is the tridemic something we could have predicted?
It’s predictable that we’d be seeing higher virus rates at this time of year, when we’re spending more time inside sharing air. But the severity of the illnesses has been unexpected. I wouldn’t say that what has happened over the past couple of months was predictable—the Covid we’re dealing with today is not the Covid of previous years. The virus has changed its game, which is what viruses do to be successful. They have to figure out how to fool people’s immune systems, which they can do by mutating, just as the new Kraken variant has. The flu and the common cold are both incredibly good at mutating, which is why they’re back year after year. And they can also reinfect people by figuring out how to hinder the immune system. This is what measles does, and it’s looking more and more like this is what’s happening with Covid: the virus is harming immune systems, which is why annual mainstays like RSV and influenza have been so much worse.

I’ve heard a lot of people say that their flu was way worse than their experience with Covid. But you’re saying Covid is to blame?
Exactly. I would bet that the people who had a really bad flu recently also had Covid in the past eight months or so. The same is true of young people and the amount of severe RSV we saw this season.

I thought our immune systems had just gotten weaker because we spent two years behind masks.
This idea of deferred immunity or “immunity debt” has become very popular. Even the prime minister was behind the podium last month saying that mask wearing and public health measures were to blame for all the sick children. I understand why the public may see this as plausible, because so many aspects of our bodies and minds do work that way. If you don’t exercise your muscles, you’re going to get weaker; if you don’t practise most skills, they’re going to get rusty. So we have this mental model in which the idea makes a lot of sense, but the problem is that our immune systems aren’t a muscle or a skill—it’s not a use it or lose it situation.

What kind of situation is it?
A metaphor that I have been using imagines our immune system as a photo collection. It takes a snapshot of every pathogen it encounters so that it can recognize the bad guy for next time. This is how our immune systems fight back. The photos don’t fade because they aren’t looked at for a few years; they just sit there until they are needed. When a virus mutates, it’s trying to disguise itself to evade detection. But, with Covid, the virus is also punching holes, fading or wearing out the photos—making them less and less useful as tools for identifying other viruses. Instead of immunity debt, we should be thinking about immunity theft.

On a scale from educated guess to proven scientific fact, where does your theory fall?
This isn’t my theory—American immunologist Anthony Leonardi has been the leading voice on the idea that Covid is suppressing immunity. He first introduced the premise over a year ago, and since then we’ve seen mounting evidence. That’s how science works: you have a theory and then you collect evidence that either supports or refutes it. And, in the case of immunity debt, the evidence just isn’t there. You’ve probably heard this theory of a “double cohort,” meaning two years’ worth of infants and toddlers who are now being exposed to RSV for the first time, but that already happened in fall 2021. And that theory doesn’t explain why children are getting so sick.

And immunity theft does?
That is what a lot of the evidence is pointing toward. Last year, I started following pediatric hospitalization rates in the US, which were extremely high because of the Omicron wave. I was worried that we would have a similar situation here in Canada, where our health care system really couldn’t handle the stress. I made a big stink about it, but in the end, I was happy to be wrong—or at least partly wrong. We did have record numbers of RSV in fall 2021 and winter 2022. This year, the overall infection rate was lower, but instead we had an alarming number of very sick children, which is why we had the overcrowded hospitals and children on ventilators. So what happened? What is the difference between this season and last season? The answer is that, last year, young people were, by and large, just starting to get Covid, whereas by the time RSV came this year, a large majority of young people had already been sick with Covid. And immunity theft may have evolved over the past year as well.

You mentioned evidence. Have there been studies to support what you’re saying?
There have been studies looking at the way Covid causes T-cell exhaustion. We now know that the virus can directly infect T cells (the guardian cells that spot infections and help defend the immune system), which we didn’t know before. There was also a study conducted by a group of pediatric specialists at several American hospitals where they looked at three groups of babies. The first group had RSV and Covid at the same time with very high viral loads, which sounds bad; the second group had RSV and Covid at the same time with low viral loads, which sounds less bad; the third group was babies who had RSV and had previously recovered from Covid. It was this last group that was by far the sickest—the ones that had to be ventilated. But it was a small study. You need more participants in order to get a consistent result. And of course it could be a giant coincidence, but it is frighteningly in keeping with this idea of immune system harm.

There are some experts who say that the threat of RSV is behind us and that the flu also seems to be winding down. Doesn’t that suggest things are getting better?
RSV season is like clockwork: it arrives late fall through December, so the fact that rates are coming down doesn’t tell us anything. And flu rates may be declining at this moment, but the flu is a very slippery customer. The virus changes every year, and the timing of the peak is always different. I think we need to watch what happens over the next few weeks: if we’ve got a population of immune-damaged babies and small children, the flu could get really ugly. And the other thing to look out for are fungal infections, which are no big deal with a healthy population, but if we’re dealing with a population with weakened immune systems, that could get really bad.

And, still, the prime minister and even Ontario’s chief medical officer of health are saying that masks are part of the problem. Does that just make you want to scream?
I was appalled to see the prime minister making those comments. And then, shortly after that, he was at a mall pressing his face up against a bunch of children—no mask. That’s the big problem with the false narrative of immunity debt: it’s encouraging people to do the exact opposite of what we need to be doing to keep everyone safe. You hear people saying that we should all just get out there and expose ourselves, but there could not be a worse strategy. I know it’s the same story and people are tired of it, but we should all still be trying not to get Covid. And, if you have had Covid, you want to be even more careful about avoiding other infections. I get it: people are tired and they just want to get back to the happy normality of 2019, which is very appealing. I want that too—I’m just not willing to step away from science to find comfort.



Read original article here

Study explores incidence, severity, and long COVID associations of SARS-CoV-2 reinfections

In a recent study posted to the medRxiv* preprint server, a team of researchers from the United States used electronic health records to characterize the incidence, biomarkers, attributes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfections and evaluated the association between reinfections and long coronavirus disease (COVID).

Study: SARS-CoV-2 Reinfection is Preceded by Unique Biomarkers and Related to Initial Infection Timing and Severity: an N3C RECOVER EHR-Based Cohort Study. Image Credit: Ralf Liebhold/Shutterstock

Background

The emergent SARS-CoV-2 variants are increasing the incidence of breakthrough infections. Mutations in spike protein regions of these variants that increase immune escape, combined with the waning of the immunity induced by coronavirus disease 2019 (COVID-19) vaccines and previous SARS-CoV-2 infections are resulting in a rise in reinfections. Studies based on whole genome sequences of the SARS-CoV-2 variants isolated from reinfected patients have revealed that the variants responsible for reinfections are distinct from those that caused the earlier infections. However, there is a dearth of information on whether reinfections differ from the initial infection in their incidence, severity, and attributes, as well as on the long COVID complications after SARS-CoV-2 reinfections.

About the study

In the present study, the team used electronic health record data of a cohort exceeding 1.5 million individuals involved in the National COVID Cohort Collaborative (N3C), which is a part of the National Institute of Health’s Researching COVID to Enhance Recovery (RECOVER) initiative. This data was used to evaluate the incidence, biomarkers, and attributes of SARS-CoV-2 reinfections and understand the association between post-acute sequelae of SARS-CoV-2 infection (PASC) and reinfections.

Reinfection was defined based on a positive SARS-CoV-2 antigen or polymerase chain reaction (PCR) test more than 60 days after the index date for the initial SARS-CoV-2 infection. Long COVID was defined based on the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes.

Reinfections were also examined according to the epochs of SARS-CoV-2 variants, with the epoch of the wild-type strain spanning the March to November 2020 period, the Alpha, Beta, and Gamma variants dominating the December 2020–May 2021 period, and the Delta variant epoch spanning the June 2021–October 2022 period. The Omicron epoch was divided into two parts for the Omicron variant and the Omicron BA variants, corresponding to November 2021–March 2022 and March–August 2022, respectively.

Biomarkers such as inflammation, coagulopathies, and organ dysfunction can be used to characterize SARS-CoV-2 infections. A wide range of biomarkers, including laboratory measurements of white blood cell counts, erythrocyte sedimentation rates, C-reactive protein, serum creatinine, albumin, and many more, were used to characterize reinfections.

COVID-associated hospitalization data was used to determine the severity of reinfections. Mild infections included those that did not require a visit to the emergency department or hospitalization, while those requiring hospitalization were categorized as moderately severe, and cases requiring hospitalization, invasive mechanical ventilators, vasopressors, or extracorporeal membrane oxygenation were considered severe infections.

The period between reinfection and long COVID diagnoses was compared with that between the initial infection and diagnosis of long COVID to understand the relationship between reinfections and PASC.

Results

The results indicated that most individuals in the cohort had one reinfection, with a small group comprising largely of non-Hispanic White males and older individuals having had three or more reinfections. The largest number of reinfections during the Omicron epoch were among individuals who had initial SARS-CoV-2 infections during the epochs of the wild-type, Alpha, Beta, and Gamma strains, followed by reinfections among those with initial Delta infections.

Analyses of biomarkers revealed that compared to the initial SARS-CoV-2 infection, reinfections showed lower elevation of hepatic inflammation markers such as alanine transaminase (ALT) and aspartate transaminase (AST). However, albumin levels were consistently low in reinfection patients.

Furthermore, the severity of reinfections was found to be associated with the severity of the initial SARS-CoV-2 infections. A majority of the cohort experienced mild symptoms during the initial infections and reinfections and did not require hospitalization or a visit to the emergency department. Compared to the initial infection, the percentage of individuals who required hospitalization or succumbed to the infection after reinfection was marginally lower (14.4% vs. 12.6%). Close to half the patients who experienced a severe initial SARS-CoV-2 infection had moderate symptoms requiring hospitalization or emergency department visits during reinfection. Additionally, 7.4% of the individuals who had a severe initial infection had severe infections, and 5.7% succumbed to the reinfection.

Long COVID diagnoses also occurred in a shorter time frame for infections or reinfections during the Omicron epoch, as compared to infections during the Delta epoch or those with other variants.

Conclusions

Overall, the results indicated that the severity of SARS-CoV-2 reinfections was similar to those of the initial infection, with individuals who experienced mild to moderate symptoms during the first infection having similar symptoms during reinfection, while individuals who experienced a severe initial infection having similar reinfection symptoms or succumbing to the disease after reinfection.

Additionally, the study reported that long COVID diagnoses during the Omicron epoch occurred much closer to the index date of the infection or reinfection, and the number of long COVID diagnoses also showed an increase after reinfections with recent variants.

*Important notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:

  • Emily Hadley, Yun Jae Yoo, Saaya Patel, Andrea Zhou, Bryan Laraway, Rachel Wong, Alexander Preiss, Rob Chew, Hannah Davis, Christopher G Chute, Emily R Pfaff, Johanna Loomba, Melissa Haendel, Elaine Hill, Richard Moffitt. (2023). SARS-CoV-2 Reinfection is Preceded by Unique Biomarkers and Related to Initial Infection Timing and Severity: an N3C RECOVER EHR-Based Cohort Study:  and the N3C and RECOVER consortia. medRxiv. doi: https://doi.org/10.1101/2023.01.03.22284042 https://www.medrxiv.org/content/10.1101/2023.01.03.22284042v1

Read original article here

How To Avoid Getting Sick While Traveling, According To Health Experts

With the holidays upon us, many of us are hitting the road (or the sky) in order to meet up with far-away family members or just get a little bit of a winter vacation in. And while travel is certainly exciting (especially at this time of year), it can also put a strain on your immune system, which is why it’s important to remember that your health should be a top priority.

With unfamiliar environments, the potential for exposure to new germs, and cold and flu season in full swing, you shouldn’t forget to take precautions to protect your health while on the go. To help you stay healthy while traveling, we’ve compiled some expert tips from Dr. Amit Arwindekar, medical director for UnitedHealthcare Global. Find all of his fantastic insight below!

 

 

 

75+ Gift Ideas For Everyone On Your Holiday List

Shutterstock

1. Anticipate potential health issues

As much as we hope that everything will always go smoothly when we travel, it’s important to anticipate the worst–or at least a bit of a hiccup–and take steps to prevent any possible health issues.  “Consider a wellness checkup with a primary care doctor before departure to talk about travel plans,” Dr. Arwindekar says. “Packing a portable health kit may also prove helpful, so consider including items such as anti-inflammatory pain relievers, first-aid supplies, earplugs, sunscreen and sunburn relief, motion-sickness remedies and insect repellents.” Noted!

READ MORE:

The Vitamin C-Packed Food You Should Be Eating Right Now For Gut Health And Immunity

A Mental Health Expert Tells Us How To Stay Stress-Free This Holiday Season

Shutterstock

2. Refill medications

Dr. Arwindekar also reminds us of the importance of refilling prescriptions and packing extra doses. You can’t keep your health in the best shape if you don’t have the medication your body needs to thrive! “Before any trip, it is a good idea to refill medications and pack extra doses in case of travel delays,” he says. “When traveling by airplane, always pack medication in carry-on luggage to help ensure access. For international travel, be sure to check prescription drug restrictions for each country to help avoid the risk of medications being confiscated.”

Shutterstock

3. Reduce jet lag

Jet lag isn’t only frustrating to deal with–it can also take a toll on your health, which is why taking measures to reduce it as much as possible is vital. “To help avoid jet lag, get lots of rest before a trip, and drink plenty of water before, during and after flights. Then, make a point to get plenty of sunlight during the day, which can help to reset the body’s internal clock,” Dr. Awindekar says. “Proper sleep can help strengthen the immune system, better regulate appetite and aid in recovery from injury.” Plus, health benefits aside, you’ll be able to enjoy your trip much better when you’re feeling well-rested.

READ MORE:

Do Wellness Shots Really Work? We Asked Experts

This Is The Best Alternative To Soda For Weight Loss, According To Experts

Shutterstock

4. Stay active

The importance of exercise doesn’t go away just because you’re on vacation! “Exercise is a great choice for helping to reduce stress and improve mood,” Dr. Awindekar reminds us. “Incorporating physical activity into sightseeing is one strategy for staying active. Using a fitness app may also help, providing access to thousands of workouts, from high-intensity interval training to yoga, and meditation.” No matter how you choose to do it, finding time to get up and move every day can do wonders for your health–even when you’re away from home.

The bottom line

By following these tips from Dr. Arwindekar, you can help protect your health and enjoy your travels to the fullest. Of course, don’t forget to also take standard precautions like washing your hands frequently, avoiding contact with sick individuals, and following local health guidelines to minimize your risk of illness. With a little planning and care, you can have a safe and enjoyable trip. Happy holidays!

; if (!f._fbq)f._fbq = n; n.push = n; n.loaded = !0; n.version = '2.0'; n.queue = []; t = b.createElement(e); t.async = !0; t.src = v; s = b.getElementsByTagName(e)[0]; s.parentNode.insertBefore(t, s) }(window, document, 'script', '//connect.facebook.net/en_US/fbevents.js');

fbq('init', '1230911863589528'); fbq('track', "PageView");

Read original article here

What is immunity debt? What does it mean for cold and flu season?

This fall, America’s pediatric hospitals have been overwhelmed by a “tri-demic” of RSV, flu, and Covid-19. And while it’s not a surprise to see respiratory viral infections hit hard at this time of year, what is surprising is to see so many of these viruses hit so many parts of the country so hard at the same time.

Why is everyone so sick, so simultaneously? One explanation that’s gotten a lot of airtime is the concept of “immunity debt,” coined by a group of French pediatric infectious disease experts in an August 2021 publication.

A central premise of immunity debt is that for many infectious diseases, repeat infections are milder than the first infection. The authors hypothesized that after several pandemic years during which masks, distancing, and ventilation protected so many people from initial infections with a range of viruses, more people than usual would be catching certain diseases for the first — and worst — time now that those protections are not as strongly in place.

At the same time, suboptimal vaccination rates for flu, Covid-19, and other vaccine-preventable diseases — due to pandemic disruptions — meant there would be less protection than usual from vaccine-preventable diseases.

The core concepts of the authors’ idea have been muddled by the internet’s inevitable game of telephone, and some experts reject the term as misleading. Inaccurate interpretations of the concept suggest its originators think the pandemic era somehow broke our immune systems, and are being used to armchair-quarterback the wisdom of masking, school closures, vaccines, and other mitigation measures that saved lives.

In fact, the fundamentals of immunity debt make a lot of sense, immunologists and infectious disease experts told me. While the term is new, the concepts it describes are actually well-trodden ideas in epidemiology.

There are still lots of unanswered questions about why respiratory viral dynamics have taken the shape they have over the past few months and years. For now, here’s what we know about the concept, and how it can be dangerously misinterpreted.

The “debt” in immunity debt is actually a surplus — of infection-susceptible people

When we think of debt, most of us think of a deficit, a lack or low supply of something. It might be more intuitive to instead understand this phenomenon as a surplus of susceptible people, especially children.

That is to say: In pre-pandemic times, young children would be exposed to and develop some immunity to a variety of infections in just the first few years of life. During the pandemic, children were still being born — but they weren’t being exposed to infections at nearly the same rate. That means that in many parts of the world, there are nearly three years’ worth of new children with relatively naive, and therefore vulnerable, immune systems, explained Ron Dagan, a doctor and researcher who specializes in pediatric respiratory infections at Israel’s Ben-Gurion University of the Negev.

“A whole cohort is born without exposure, so all of them will be having much lower antibodies than normal — so there will be much more susceptibility to infections,” Dagan said.

There are a few reasons for this immunological naivete, some of them obvious. Social distancing and masking meant that many babies born during this time simply didn’t have contact with the usual number of other children who might have been sick. For a year, many kids didn’t go to school or day care — places where they traditionally encounter lots of infections. And even though many schools and day cares opened up in the fall of 2021, many had mask mandates in place for staff and children during the coldest part of the year, when opening windows and moving class outdoors were least likely to be used as preventive measures.

But other reasons for lower protection levels have more to do with lower levels of infection in adults — specifically, pregnant adults. During the first year of life, most of babies’ infection protection comes in the form of antibodies passed on to them naturally during pregnancy and breastfeeding. The degree of protection newborns have corresponds to their birthing parent’s level of protection.

“If you’re born to mothers with higher antibody levels, you will be more protected,” said Dagan.

For the first two and a half years of the pandemic — before companies began requiring employees to return to the office, and before other pandemic-era measures became far less commonly used — pregnant people, like other adults, weren’t catching colds as often.

Due to systemic inequities, that reprieve wasn’t experienced to the same extent by all Americans. Still, on a population level, many of the babies born during those years didn’t receive as many antibodies during pregnancy or breastfeeding — and were therefore born more vulnerable to common infections.

Several of the experts I spoke with thought that most of the sick children currently being hospitalized would probably have been hospitalized in 2020 or 2021 if they’d been infected back then. In other words, they said, what makes the current hospitalization surge so large is that it represents a backlog of severe infections that, while inevitable, would have caused less of an onslaught if it had been spread out over two-plus years.

All told, the population is more vulnerable to widespread transmission of some respiratory viruses. And because infections in people without immunity are usually more severe than in people with some immunity, that translates to more people at risk of getting sicker when they catch what would otherwise be a casual winter cold. However, it does not mean our individual immune systems are weak or “out of practice,” say epidemiologists.

This is the key source of confusion, experts tell me. While past colds and illnesses from previous seasons can protect us from current outbreaks conditions, there really isn’t such thing as a “good cold.” We shouldn’t seek out sickness for ourselves or our children. When you go looking for viruses, you never know what you’re going to catch.

Preventing respiratory infections is a good thing. That’s an important fact that misinterpretations of “immunity debt” get wrong.

Remember the hygiene hypothesis? That’s the theory that overly clean environments prevent healthy children’s immune systems from getting the “education” they need to respond adequately to infectious organisms. Without that education, goes the theory, the immune system compensates by overreacting, leading children to develop allergies, asthma, and other problems of immune system dysregulation.

In many people’s imaginations, the hygiene hypothesis means the more colds children are exposed to early in life, the more protective their immune systems are later in life. But there are very real risks with taking an open-door approach to catching colds, said Steven Varga, an immunologist at the University of Iowa who studies viral respiratory infections.

For starters, when it comes to respiratory viruses, you never know what you’re breathing in: a mild virus that will cause a few days of snot, or something more deadly. It’s impossible to game out getting a mild infection, said Varga. “You can’t prevent one kind of respiratory tract infection and allow the others to go through,” he said.

If people are unprotected against less virulent pathogens like rhinovirus, for example, they’re also unprotected against viruses that can cause real damage, like RSV and SARS-CoV-2. That creates threats to those known to be at risk for severe infection from these viruses, like older and immunocompromised people.

Again, trying to get sick on purpose is a dangerous game of roulette. However, Varga cautioned that it’s impossible to predict who will get super-sick with a pathogen — even healthy people can get unexpectedly and severely ill. The vast majority of kids hospitalized for RSV are otherwise healthy, he said. “We can’t predict with any great certainty who is at increased risk for that more severe disease.”

The most helpful germs for our immune system are mostly ingested, not inhaled

There are also misconceptions, the researchers say, about which microbes help “train” our immune system most effectively. It’s not respiratory viruses like the cold and flu.

Rather, it’s the billions of microbes that live peacefully in our bodies, sometimes called the microbiome, said Marsha Wills-Karp, an immunologist at Johns Hopkins Bloomberg School of Public Health who studies the environmental determinants of allergic airway diseases.

Within that microbiome, there are many “teachers,” like bacteria that educate infants’ immune systems to develop lymphoid centers, the B-cell factories that contribute to antibody production, or that train macrophages and other immune cells to respond to pathogenic invaders (i.e., germs).

A lot of work that’s supported the hygiene hypothesis suggests that most of the microbiome’s important immune system education originates in the gut — and, therefore, that what kids swallow contributes more to their immune development than what they breathe in.

Additionally, it’s not currently clear how many of those helpful microbes are viruses — largely because most microbiome work has been on bacteria.

There is a small microbiome in the upper airways and the lungs, but it’s much less diverse than the digestive tract’s, said Wills-Karp. Although the respiratory microbiome does play a role in health and disease states, “in population studies and animal studies, the hygiene hypothesis seems to be more linked to a healthy gut microbiome,” she said.

The bottom line here: There’s currently not much evidence to support the idea that adding more viruses to a person’s respiratory tract does anything to improve the immune system or to otherwise improve health.

Wills-Karp recommends training young immune systems the way you might train a young football player: with players you know they can handle. Kids should run drills with other players their own size, not with an NFL team, “because there’s more potential for you to get hurt with the big boys,” she said. Similarly, immune systems should get trained on the safe environmental and comestible microbes that live in our guts — exposures children and adults get anyway by living in non-sterile environments, but which are enriched by certain factors like living with animals and eating fermented and fiber-rich foods.

The best cold virus is the one you don’t catch

Instead of relying on direct exposure for the little protection it might provide, a safer bet is to train our immune systems using vaccines whenever we can. Flu and Covid-19 vaccines are available now, and RSV vaccines will likely be approved within the next few years.

Also a safer bet — for immune systems young, old, and everywhere in between — is not getting sick to begin with. Wearing masks, maximizing our indoor air’s ventilation and filtration, and other pandemic-era strategies prevent more than just Covid-19.

There are still a ton of unanswered questions about respiratory viruses and how they impact our health later in life. A big one surrounds the link between asthma and severe RSV disease: Babies with bad RSV infections are more likely to go on to develop asthma, but the medical community has never fully understood whether the infection causes the asthma, or instead, whether the factors that predispose a child to asthma make severe RSV more likely.

Other big questions revolve around the cause, treatment, and overall footprint of post-viral syndromes like long Covid, and the role (if any) of viral interference — meaning, when one viral infection reduces or enhances the severity of a second viral infection — in respiratory virus trends. But one of the most pressing questions, said Dagan, involves what we can expect from these pathogens in the near term. Will next year bring another explosive respiratory virus season? Right now it’s impossible to say.

We do know the immunity boost that follows infections with RSV and certain flu strains is probably only enough to protect people for about a year afterward. But overall, viral outbreaks are easier to explain in retrospect than they are to predict (although, it should be noted, the authors of the “immunity debt” paper did accurately foretell the current RSV surge).

“We don’t know how these viruses will behave in the next two or three years,” or what the SARS-CoV-2 virus will look like a year from now, and whether any changes might portend different impacts on children and adults, he said. “There are too many questions that we can ask — and every answer brings you more questions.”

Read original article here

With record covid cases, China scrambles to plug an immunity gap

Comment

A coronavirus outbreak on the verge of being China’s biggest of the pandemic has exposed a critical flaw in Beijing’s “zero covid” strategy: a vast population without natural immunity. After months with only occasional hot spots in the country, most of its 1.4 billion people have never been exposed to the virus.

Chinese authorities, who on Thursday reported a record 31,656 infections, are scrambling to protect the most vulnerable populations. They have launched a more aggressive vaccine drive to boost immunity, expanded hospital capacity and started to restrict the movement of at-risk groups. The elderly, who have an especially low vaccination rate, are a key target.

These efforts, which stop short of approving foreign vaccines, are an attempt to keep the virus from overwhelming a health-care system ill-prepared for a flood of very sick covid patients.

More intensive-care beds and better vaccination coverage “should have started 2½ years ago, but the single-minded focus on containment meant fewer resources focused on this,” said Yanzhong Huang, a senior fellow for global health at the Council on Foreign Relations.

Huang believes that even mRNA boosters, which have proved more effective at fighting disease from the latest omicron variants, wouldn’t now resolve the fundamental problem with China’s goal of eliminating infection rather than mitigating symptoms. To raise immunity by allowing a degree of community transmission “is still not acceptable in China,” he said.

China’s strategy of smothering outbreaks originally protected everyday life and the economy while preventing severe illness and death. But it has become increasingly costly as ever-stricter measures fail to keep up with more-transmissible variants.

Earlier this month, the government announced what on paper appeared to be the most significant easing of controls so far, with shorter quarantine times and fewer testing requirements. Officials insist that the 20-point “optimization” plan is not a prelude to accepting outbreaks.

But the effort to break cycles of disruptive lockdowns has had a rocky start. Some cities relaxed measures, while districts in others ordered residents not to set foot outside their homes. The result: confusion, fear and anger.

Confrontations have erupted in a few locations, most prominently at a huge Foxconn plant in central China that makes half the world’s iPhones. The scene there turned violent this week as thousands of workers protested the company’s failure to isolate people testing positive and to honor the terms of employment contracts.

Curbing outbreaks is again taking priority. Shijiazhuang, a city of 11 million about 185 miles from the capital, suspended its reduced requirements for mass testing on Monday and announced five days of citywide screening.

The first deaths to be reported since May — though only one or two per day — have intensified concerns that hospitals are poorly prepared to handle a surge in severe cases. Bloomberg Intelligence estimated that fully relaxing coronavirus controls could leave 5.8 million Chinese needing intensive care in a system with only four beds per 100,000 people.

At a news conference Wednesday, Chinese health officials said the 100-plus critical cases meant more hospital beds and treatment facilities were “very necessary” given the health risks for the elderly and individuals with preexisting conditions. The spread of infection was accelerating in multiple locations, they added, with some provinces facing their worst outbreaks in three years.

Major cities including Beijing, Guangzhou and Chongqing have ordered residents in certain neighborhoods to stay at home. Shopping malls, museums and schools have been closed once more. Major conference centers are being turned back into temporary quarantine centers, reflecting the approach adopted in Wuhan at the start of the pandemic. Some of the tightest restrictions are for nursing homes, with 571 such facilities in Beijing implementing the strictest tier of control measures and preventing all but essential exit and entry.

Opening to a world that’s now mostly living with the virus would cause a wave of deaths, officials fear. China’s vaccines initially were limited to adults ages 19 to 60, a policy that continues to have repercussions for vaccination rates today. Just 40 percent of Chinese older than 80 have received a booster shot, despite months of campaigning and gift-giving to encourage uptake. (Among people older than 60, two-thirds have gotten a booster.)

Since the beginning of the pandemic, China has relied solely on domestic vaccine makers. It approved nine locally developed options, more than any other country, with the earliest and most-used vaccines coming from state-owned Sinopharm and privately owned Sinovac. Both received approval from the World Health Organization early last year after being found to significantly reduce deaths and hospitalizations.

Sinopharm and Sinovac distributed their products widely throughout the world as part of a Chinese push to become a leading provider of global public goods and to improve China’s image. Yet in late 2021, demand for Chinese vaccines started to dry up as Pfizer’s and Moderna’s production and distribution increased.

China has still not approved any foreign vaccines or explained its decision to shun what could be an effective way to plug its immunity gap. A visit by German Chancellor Olaf Scholz to Beijing in early November ended with an agreement for the Pfizer-BioNTech vaccine to be made available to foreigners living in China via the company’s Chinese partner, Shanghai Fosun Pharmaceutical.

BioNTech has a development and distribution deal with Fosun that gives the Chinese company exclusive rights to supply the country. But Chinese regulators have repeatedly delayed signing off on the vaccine, despite it being made available in Hong Kong, Macao and Taiwan.

When asked last week if the government would approve BioNTech for public use, the director of the Chinese Center of Disease Prevention and Control said authorities were working on a new vaccination plan to be released soon.

Without access to the most effective mRNA-based candidates from Pfizer-BioNTech and Moderna, which have been updated to fight the omicron variant, the world’s most populous country remains reliant on vaccines developed using the original strain of the virus.

Some health experts consider Beijing’s reticence hard to justify. “China should approve the BioNTech and Moderna vaccines for the general Chinese population as soon as possible,” said Jin Dong-yan, a virologist at the University of Hong Kong. “It’s ridiculous that they only allowed foreigners in China to receive the BioNTech vaccine. It is as if they think Chinese people are inferior to foreigners.”

China is instead trying to develop 10 of its own mRNA candidates. The one furthest along is from biotechnology group Abogen Biosciences and the state-run Academy of Military Medical Sciences. Indonesia approved it for emergency use in September, but it has not received the nod from Chinese regulators and may not get that until data is available from Phase 3 clinical trials in Indonesia and Mexico. The trials are expected to conclude in May.

Other options in China include an inhalable vaccine developed by CanSino, which has been available in Beijing, Shanghai and Hangzhou since October. A Chinese-developed antiviral drug, Azvudine, originally used for HIV patients, was approved to treat covid in July. Traditional Chinese medicines are widely used.

But new and more-effective vaccines remain a top priority, and the country’s leading pharmaceutical companies are poised to mass-produce them. CanSino is completing a production facility in Shanghai that will be able to manufacture 100 million doses a year — after receiving approval.

Read original article here

A Bizarre Case of Hypertension Immunity

By

High blood pressure nearly always causes the heart to become weaker.

Surprisingly, certain patients with the mutated PDE3A gene were immune to hypertension-related damage.

Scientists in Berlin have been studying a strange hereditary condition that causes half the people in certain families to have shockingly short fingers and abnormally high blood pressure for decades. If untreated, affected individuals often die of a stroke at the age of 50. Researchers at the Max Delbrück Center (MDC) in Berlin discovered the origin of the condition in 2015 and were able to verify it five years later using animal models: a mutation in the phosphodiesterase 3A gene (PDE3A) causes its encoded enzyme to become overactive, altering bone growth and causing blood vessel hyperplasia, resulting in high blood pressure.

Immune to hypertension-related damage

“High blood pressure almost always leads to the heart becoming weaker,” says Dr. Enno Klußmann, head of the Anchored Signaling Lab at the Max Delbrück Center and a scientist at the German Centre for Cardiovascular Research (DZHK). As it has to pump against a higher pressure, Klußmann explains, the organ tries to strengthen its left ventricle. “But ultimately, this results in the thickening of the heart muscle – known as cardiac hypertrophy – which can lead to heart failure greatly decreasing its pumping capacity.”

Short fingers in one family. Credit: Sylvia Bähring

However, this doesn’t happen in hypertension patients with short fingers and mutant PDE3A genes. “For reasons that are now partly – but not yet fully – understood, their hearts appear immune to the damage that usually results from high blood pressure,” says Klußmann.

The research was conducted by scientists from the Max Delbrück Center, Charité – Universitätsmedizin Berlin, and the DZHK and has been published in the journal Circulation. In addition to Klußmann, final authors included Max Delbrück Center professors Norbert Hübner and Michael Bader, as well as Dr. Sylvia Bähring from the Experimental and Clinical Research Center (ECRC), a joint institution of Charité and the Max Delbrück Center.

The team, which included 43 other researchers from Berlin, Bochum, Heidelberg, Kassel, Limburg, Lübeck, Canada, and New Zealand, has recently published their findings on the protective effects of the gene mutation – and why these discoveries might transform the way heart failure is treated in the future. The study has four first authors, three of which are Max Delbrück Center researchers and one at the ECRC.

Cross-section through a normal heart (left), through one of the mutant hearts (center), and through a severely hypertrophic heart (right). In the latter, the left ventricle is enlarged. Credit: Anastasiia Sholokh, MDC

Two mutations with the same effect

The scientists performed their tests on human patients with hypertension and brachydactyly (HTNB) syndrome – i.e., high blood pressure and abnormally short digits – as well as on rat models and heart muscle cells. The cells were grown from specially engineered stem cells known as induced pluripotent stem cells. Before testing began, researchers altered the PDE3A gene in the cells and the animals to mimic HTNB mutations.

“We came across a previously unknown PDE3A gene mutation in the patients we examined,” reports Bähring. “Previous studies had always shown the mutation in the enzyme to be located outside the catalytic domain – but we have now found a mutation right in the center of this domain.” Surprisingly, both mutations have the same effect in that they make the enzyme more active than usual. This hyperactivity ramps up the degradation of one of the cell’s important signaling molecules known as cAMP (cyclic adenosine monophosphate), which is involved in the contraction of the heart muscle cells. “It is possible that this gene modification – regardless of its location – causes two or more PDE3A molecules to cluster together and thus work more effectively,” Bähring suspects.

The proteins stay the same

The researchers used a rat model – created with CRISPR-Cas9 technology by Michael Bader’s lab at the Max Delbrück Center – to try to better understand the effects of the mutations. “We treated the animals with the agent isoproterenol, a so-called beta-receptor agonist,” says Klußmann. Such medications are sometimes used in patients with end-stage heart failure. Isoproterenol is known to induce cardiac hypertrophy. “Yet surprisingly, this occurred in the gene-modified rats in a manner similar to what we observed in the wild-type animals. Contrary to what we expected, the existing hypertension did not aggravate the situation,” reports Klußmann. “Their hearts were quite obviously protected from this effect of the isoproterenol.”

In further experiments, the team investigated whether proteins in a specific signaling cascade of the heart muscle cells changed as a result of the mutation and if so which ones. Through this chain of chemical reactions, the heart responds to adrenaline and beats faster in response to situations such as excitement. Adrenaline activates the cells’ beta receptors, causing them to produce more cAMP. PDE3A and other PDEs stop the process by chemically altering cAMP. “However, we found little difference between mutant and wild-type rats at both the protein and the

Read original article here

White House press secretary explains decision to request immunity for crown prince in killing of Khashoggi

White House press secretary Karine Jean-Pierre explained the Biden administration’s decision to request immunity for Saudi Arabia’s Crown Prince, Mohammed bin Salman in lawsuits over his alleged role in the killing of Washington Post journalist Jamal Khashoggi in 2018.

“So, look, again, this is immunity. Determination is a legal one. That’s what I was laying out earlier. The United States consistently has afforded head of state immunity to heads of government, such as prime ministers consistent with customary institutional law,” Jean-Pierre said. “U.S. practice on this issue is longstanding and consistent, including a number of head of state immunity cases from the past four administrations.”

Her comments come after the State Department made the determination on Thursday that Prince Mohammed, also referred to as MBS, should be immune from lawsuits over his alleged role in the death of Khashoggi.

The State Department called the decision “purely a legal determination,” citing longstanding precedent on the issue.

BIDEN ADMINISTRATION REQUESTS IMMUNITY FOR SAUDI CROWN PRINCE IN KHASHOGGI KILLING: ‘BEYOND IRONIC’

President Biden being welcomed by Saudi Arabian Crown Prince Mohammed bin Salman at Alsalam Royal Palace in Jeddah, Saudi Arabia on July 15. The prince reportedly mocked Biden in private and said he is unimpressed with him. 
(Royal Court of Saudi Arabia / Handout/Anadolu Agency via Getty Images)

In the filing, the State Department said that it “takes no view on the merits of the present suit and reiterates its unequivocal condemnation of the heinous murder of Jamal Khashoggi.”

When President Biden was running for his current office in 2019, he said that he planned to make a “pariah” of Saudi leaders over Khashoggi’s death. He made the comments during a Democratic primary debate in 2019.

BIDEN CONFRONTS SAUDI CROWN PRINCE ON KHASHOGGI KILLING

White House press secretary Karine Jean-Pierre talks to reporters during the daily news conference in the Brady Press Briefing Room at the White House.
(Chip Somodevilla/Getty Images)

At a 2019 CNN town hall, Biden called the incident “flat-out murder.”

CLICK HERE TO GET THE FOX NEWS APP

Biden’s meeting Monday with Xi was the first time the two have met since Biden became president.
(AP/Alex Brandon)

“And I think we should have nailed it as that. I publicly said at the time we should treat it that way and there should be consequences relating to how we deal with those — that power,” Biden said.

Fox News’ Elizabeth Pritchett and The Associated Press contributed to this report.

Read original article here

Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses – Science

  1. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses Science
  2. Updapted BA.4/5 COVID vaccines boost protection but might not surpass original formula News-Medical.Net
  3. Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial The Lancet
  4. Evolution of naturally arising SARS-CoV-2 defective interfering particles | Communications Biology Nature.com
  5. Is vaccine status associated with the severity of Omicron SARS-CoV-2 infection in hospitalized patients? News-Medical.Net
  6. View Full Coverage on Google News

Read original article here

Record numbers of toddlers are hospitalized with colds because immunity was weakened by restrictions

More children and young people are being hospitalized with colds and respiratory problems than ever after the Covid pandemic, official data suggests.

Experts have repeatedly warned lockdowns and measures used to contain Covid like face masks also suppressed the spread of germs which are crucial for building a strong immune system in children.

A retrospective report by the Centers for Disease Control and Prevention (CDC) today showed levels of common cold viruses hit their highest level ever among under-18s in August 2021.

The CDC samples random pediatric hospitals across the US and makes national estimates to gauge how prevalent viruses are. 

There were nearly 700 children in hospital sick with a respiratory virus across the seven wards studied in August last year, of which just over half had tested positive for respiratory syncytial virus (RSV) – which is normally benign.

This was the highest levels ever recorded in summer, and came off the back of a year and a half of brutal pandemic restrictions forcing many to stay indoors.

The record all-time high is in December, when 60 per cent of children on wards with respiratory illnesses were infected with RSV.

While the report only looked at August 2021, separate data from the CDC indicates that hospital visits for children under four years old with respiratory problems may be getting worse. 

In the week ending September 18 this year, of all emergency department visits for toddlers 4.7 per cent were for breathing difficulties across the US — a record high.

Dr Scott Roberts, a medical director at Yale University, today told DailyMail.com that lockdowns robbed children of the chance to build up immunity to common bugs.

The above shows the proportion of ER visits among children aged 5 to 14 years that were due to reactive respiratory disease / asthma. It reveals that there has been an uptick as well, but that this is similar to periods before the pandemic

The above graph shows the number of children less than 18 years old who were admitted to seven hospitals in the US for respiratory illnesses, which were taken to be nationally representative (grey bars). Each was then tested for respiratory viruses, with their results shown by the lines. Data showed infections of respiratory syncytial virus (RSV, black line) hit their highest level ever in summer during last August (red circle). The red arrows show the other August’s on the graph

The above graph shows the proportion of ER visits among children aged 0 to 4 years that were due to reactive respiratory disease / asthma — a term for cases where children suffer a severe cough. It shows that during 2021 the proportion hit its highest level since records began

The record rise was revealed today in the Morbidity and Mortality Weekly Report (MMWR), the country’s premier publication on infectious diseases and healthcare.

Scientists monitored seven hospitals in the US for the number of children who had been admitted for respiratory illnesses. These hospitals were in seven states including Washington, Texas, New York and Ohio.

All participants had at least one symptom of a respiratory disease including a cough, earache, runny nose, sore throat and shortness of breath.

Each was then tested to determine which disease they had been infected with. This does not necessarily mean that they had been hospitalized because of this disease.

The report does not include data for the rest of 2021 or into this year.

Firearm suicides rose to 30-year high in 2021 during the second year of the pandemic, CDC report finds 

Firearm suicides skyrocketed in 2021 to their highest rate in over 30 years, an alarming trend that coincided with the global Covid pandemic.

More than 26,000 Americans killed themselves using a gun in 2021, according to provisional federal data – or 55 per cent of all suicides. That marks the highest rate since 1990.

Suicides overall have increased over the past decade across age groups including teens. And the rate of teen suicides caused by guns remains high. 

About 44 per cent of suicide deaths in the 14 to 18-year-old age group were caused by guns between 2015 and 2020. 

Suicides overall rebounded last year for the first time in two years, with roughly 48,000 Americans taking their own life.

It is feared to be an early sign of the economically brutal effects of lockdowns and pandemic restrictions.

 

<!- - ad: https://mads.dailymail.co.uk/v8/de/health/none/article/other/mpu_factbox.html?id=mpu_factbox_1 - ->

Advertisement

Data showed that among the nearly 700 who were hospitalized with respiratory illnesses in August 2021 nearly 55 per cent tested positive for RSV.

Of the 450 that were moved to emergency departments, nearly 35 per cent had RSV.

This level was also comparable to the winter months when more than 30 per cent of patients regularly have the virus.

But in summer — when the data is from — this was usually at a much lower level.

Common respiratory viruses were virtually absent during the Covid pandemic as restrictions — such as face masks and stay-at-home orders — stopped them from spreading.

The ever-present COVID-19 also interfered with the ability of the annual virus to spread, as a person already infected with it was unlikely to also catch the flu.

But as society returned to normal they began to spread again and rapidly.

The knock-on effect appears to be a worrying wide in hospitalizations with common respiratory diseases.

Dr Roberts told DailyMail.com that lockdowns resulted in up to two years where children may not have been exposed to common respiratory viruses.

‘There are two implications to this,’ he said.

‘First, the gap gives time for the viruses to mutate even further to cause more severe disease.

‘And second, whatever immunity was built up to those viruses’ it will have waned making the immune response now much less potent.

Dr Roberts also told DailyMail.com how his son, who has just turned two years old, was now repeatedly coming home with infections after starting daycare.

‘We were pretty sheltered during the pandemic,’ he said.

‘But now my son has just started daycare and he is getting constant infections.’

There are also some concerns now over pediatric hospitals rapidly filling up with children ill with respiratory diseases over September, much earlier than normally occurs.

It is worrying experts about the winter, when these viruses normally spread, as it suggests there could be another wave of hospitalizations.

A separate study also published in the MMWR today also points to this risk.

After trawling national databases it found that out of the children surveyed, hospitalizations hit their highest level in mid-September for respiratory illnesses compared to the previous four years for 0 to 4-year-olds.

The previous record was set in the penultimate week of September 2019, when 4.3 per cent of babies and toddlers in emergency wards had tested positive for the respiratory illness. 

No record-breaking surge was recorded among 5 to 17-year-olds, however, with admissions for respiratory diseases being similar to the two years before the Covid pandemic struck.

Latest data showed that in September they made up around 35 per cent of admissions to emergency departments, below the level for the same period in 2018 where they made up nearer 40 per cent. 

In their paper, the scientists suggested enteroviruses — another common respiratory illness — may be behind the surge in young children.

They said: ‘This rise might be attributable, in part, to increased [enterovirus] circulation and specifically circulation of EV-D68.

‘Ongoing surveillance is necessary to understand when and where future circulation and EV-D68–associated severe illness might occur, given the potential changes in virus circulation and population immunity related to COVID-19 mitigation measures.’

Firearm suicides skyrocketed in 2021 to their highest rate in over 30 years, an alarming trend that coincided with the global Covid pandemic

No data was provided on what treatments the patients got, or how long they remained in hospital. 

Only last month the CDC warned over rising infections with enterovirus. It called on clinicians to be on the look out for cases and request tests from the CDC if needed.

It comes after separate CDC data today found firearm suicides skyrocketed in 2021 to their highest rate in over 30 years, an alarming trend that coincided with the global Covid pandemic.

More than 26,000 Americans killed themselves using a gun in 2021 – or 55 per cent of all suicides. That marks the highest rate since 1990.

Suicides overall have increased over the past decade across age groups including teens. And the rate of teen suicides caused by guns remains high. 

About 44 per cent of suicide deaths in the 14 to 18-year-old age group were caused by guns between 2015 and 2020. 

Suicides overall rebounded last year for the first time in two years, with roughly 48,000 Americans taking their own life.

It is feared to be an early sign of the economically brutal effects of lockdowns and pandemic restrictions.

Read original article here

The Ultimate News Site